Phytotherapeutics: The Rising Role of Drug Transporters in Herb-Drug Interactions with Botanical Supplements

2021 ◽  
pp. 469-494
Author(s):  
Shruti Surendran ◽  
Pooja Dhurjad ◽  
Satheeshkumar Nanjappan
Keyword(s):  
Drug Interactions ◽  
Drug Transporters ◽  
Botanical Supplements

scholarly journals Phytotherapeutics: The Emerging Role of Intestinal and Hepatocellular Transporters in Drug Interactions with Botanical Supplements

Molecules ◽  
2017 ◽  
Vol 22 (10) ◽  
pp. 1699 ◽  
Author(s):  
Ghulam Murtaza ◽  
Naveed Ullah ◽  
Farah Mukhtar ◽  
Shamyla Nawazish ◽  
Saiqa Muneer ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Botanical Supplements

Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450

2016 ◽  
Vol 17 (7) ◽  
pp. 681-691 ◽  
Author(s):  
Ruirui Yang ◽  
Zhiqiang Luo ◽  
Yang Liu ◽  
Mohan Sun ◽  
Ling Zheng ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Cytochromes P450 ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers

Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management

2021 ◽  
Author(s):  
Audrey Bellesoeur ◽  
Ithar Gataa ◽  
Anne Jouinot ◽  
Sarah El Mershati ◽  
Anne-Catherine Piketty ◽  
...  
Keyword(s):  
Risk Management ◽  
Drug Interactions ◽  
Toxicity Risk

Role of P-glycoprotein in Statin Drug Interactions

2006 ◽  
Vol 26 (11) ◽  
pp. 1601-1607 ◽  
Author(s):  
Carol W Holtzman ◽  
Barbara S Wiggins ◽  
Sarah A Spinler
Keyword(s):  
Drug Interactions ◽  
P Glycoprotein ◽  
Statin Drug

scholarly journals The Role of Drug Interactions and Monitoring in the Prevention of Tenofovir-Associated Kidney Disease

2006 ◽  
Vol 42 (11) ◽  
pp. 1657-1658 ◽  
Author(s):  
J. A. Winston ◽  
D. H. Shepp
Keyword(s):  
Kidney Disease ◽  
Drug Interactions

scholarly journals Expression of drug transporters in the human skin: comparison in different species and models and its implication for drug development

ADMET & DMPK ◽  
2017 ◽  
Vol 5 (2) ◽  
pp. 75 ◽  
Author(s):  
Hanan Osman-Ponchet ◽  
Alexandre Gaborit ◽  
Jean-Michel Linget ◽  
Claire E. Wilson
Keyword(s):  
Human Skin ◽  
Drug Absorption ◽  
Transdermal Delivery ◽  
Drug Transporters ◽  
Drug Distribution ◽  
Skin Surface ◽  
Pharmacological Intervention ◽  
Novel Targets

<p class="ADMETabstracttext">It is clear that many drug transporters (both ABCs and SLCs) are present in the human skin. Different in vitro skin models can be used to investigate the role of drug transporters in the skin despite quantitative differences in expression profile across species. P-gp was shown to have an important influence on transdermal drug absorption in the skin and to function in “absorptive” transport, carrying substrate drugs from the skin surface to the dermis. This observation might be used to modulate drug distribution inside the skin. If drugs can be retained in the epidermis compartment by inhibition of the transporters, such property of the drug would be beneficial for treatment of dermatological diseases. Therefore, it might be feasible to control transdermal delivery of drugs to specific locations in the skin, by modulating the function of the transporters in the skin. We are at the dawn of an exciting period where drug transporters might be novel targets for improvement of drug delivery to the skin and for pharmacological intervention.</p>

scholarly journals A Proof of Concept of the Role of TDM-Based Clinical Pharmacological Advices in Optimizing Antimicrobial Therapy on Real-Time in Different Paediatric Settings

2021 ◽  
Vol 12 ◽  
Author(s):  
Milo Gatti ◽  
Pier Giorgio Cojutti ◽  
Caterina Campoli ◽  
Fabio Caramelli ◽  
Luigi Tommaso Corvaglia ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Real Time ◽  
Antimicrobial Therapy ◽  
Turnaround Time ◽  
Antimicrobial Treatment ◽  
Therapeutic Drug ◽  
Proof Of Concept ◽  
Paediatric Patients ◽  
Dosing Regimens

Introduction: Antimicrobial treatment is quite common among hospitalized children. The dynamic age-associated physiological variations coupled with the pathophysiological alterations caused by underlying illness and potential drug-drug interactions makes the implementation of appropriate antimicrobial dosing extremely challenging among paediatrics. Therapeutic drug monitoring (TDM) may represent a valuable tool for assisting clinicians in optimizing antimicrobial exposure. Clinical pharmacological advice (CPA) is an approach based on the correct interpretation of the TDM result by the MD Clinical Pharmacologist in relation to specific underlying conditions, namely the antimicrobial susceptibility of the clinical isolate, the site of infection, the pathophysiological characteristics of the patient and/or the drug-drug interactions of cotreatments. The aim of this study was to assess the role of TDM-based CPAs in providing useful recommendations for the real-time personalization of antimicrobial dosing regimens in various paediatric settings.Materials and methods: Paediatric patients who were admitted to different settings of the IRCCS Azienda Ospedaliero-Universitaria of Bologna, Italy (paediatric intensive care unit [ICU], paediatric onco-haematology, neonatology, and emergency paediatric ward), between January 2021 and June 2021 and who received TDM-based CPAs on real-time for personalization of antimicrobial therapy were retrospectively assessed. Demographic and clinical features, CPAs delivered in relation to different settings and antimicrobials, and type of dosing adjustments were extracted. Two indicators of performance were identified. The number of dosing adjustments provided over the total number of delivered CPAs. The turnaround time (TAT) of CPAs according to a predefined scale (optimal, &lt;12 h; quasi-optimal, between 12–24 h; acceptable, between 24–48 h; suboptimal, &gt;48 h).Results: Overall, 247 CPAs were delivered to 53 paediatric patients (mean 4.7 ± 3.7 CPAs/patient). Most were delivered to onco-haematological patients (39.6%) and to ICU patients (35.8%), and concerned mainly isavuconazole (19.0%) and voriconazole (17.8%). Overall, CPAs suggested dosing adjustments in 37.7% of cases (24.3% increases and 13.4% decreases). Median TAT was 7.5 h (IQR 6.1–8.8 h). Overall, CPAs TAT was optimal in 91.5% of cases, and suboptimal in only 0.8% of cases.Discussion: Our study provides a proof of concept of the helpful role that TDM-based real-time CPAs may have in optimizing antimicrobial exposure in different challenging paediatric scenarios.

Scientific Perspectives on Drug Transporters and Their Role in Drug Interactions

2006 ◽  
Vol 3 (1) ◽  
pp. 62-69 ◽  
Author(s):  
Lei Zhang ◽  
John M. Strong ◽  
Wei Qiu ◽  
Lawrence J. Lesko ◽  
Shiew-Mei Huang
Keyword(s):  
Drug Interactions ◽  
Drug Transporters
Sign in / Sign up

Export Citation Format

Share Document